Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Rayonier Advanced Materials, Inc. (RYAM)
NYSEMaterialsChemicals - SpecialtySnapshot 2026-11-04
$7.15+3.47%
Close 2026-11-04 · 1-day change
NYSEMaterialsChemicals - SpecialtySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.87 → 0.89 EPS · FY ending Dec 31, 2027 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for RYAM yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve full-year EBITDA above 2025 levels | A primary condition in Rayonier Advanced Materials, Inc.'s published investment case. The stated target is full-year EBITDA > 2025 levels. | Broken | full-year EBITDA in 2026 falls below 2025 levels | Ebitda: $95M FY2026-Q2; GAAP. Published target: full-year EBITDA > 2025 levels. Annual target cannot be compared with a quarterly or TTM observation. Aug 5, 202695,000,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk recovery and strategic-review story, not a durable earnings compounder today. The long-term thesis remains on watch: operating results have improved, but recent performance is weak and the company is still loss-making.
RYAM is described as cheap versus peers, but the valuation model has low confidence and the expectations gap is negative. The evidence labels pricing as justified and fragility as low, while the company’s losses and weak results leave limited proof of a sustained recovery.
Near term, earnings risk is elevated after recent misses, and another guidance cut would be a meaningful setback. In 2026, adjusted EBITDA improved from $8 million in Q1 to $40 million in Q2, but operating cash flow fell from $32 million to $5 million; management still expects positive full-year free cash flow and EBITDA above 2025 levels.
The multi-year view depends on whether management completes its strategic review and communicates a clear path forward in Q4 2026, while sustaining the improvement in EBITDA and reaching positive free cash flow. Near-term sector signals also matter: continued strength from LIN, ECL, and SHW could support the Materials backdrop, while misses or weaker guidance could remove that tailwind.
Over the next 1 to 3 years, RYAM’s case rests on turning recent operational improvement into steadier cash generation and a clear strategic direction. Losses, repeated earnings misses, and uncertain execution keep the thesis fragile despite a supportive sector backdrop. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Deliver positive free cash flow in 2026 |
| Rayonier Advanced Materials aims to deliver positive free cash flow in 2026. |
| Improving |
| free cash flow remains negative through FY26 |
Free cash flow: $-20.347M FY2026-Q2; GAAP. Published target: positive free cash flow in 2026. Annual target cannot be compared with a quarterly or TTM observation. Aug 5, 2026-20,347,000 USD · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 3 supplied quarters. Management reported: “Our full-year trajectory remains aligned with our prior expectations, including generating positive free cash flow in 2026.” “Our priorities remain unchanged, and we continue to expect full-year EBITDA above 2025 levels and positive free cash flow in 2026.” Revenue was $382.513 million in 2026-Q3. Delivery assessment Nov 4, 2026 |
Successful leadership transition with new CEO | A new experienced CEO was appointed in 2026 to drive recovery. | Under Pressure | CEO departure or failure to improve company performance within 1 year | 3 consecutive earnings misses vs stable execution target CEO Daniel Krawczyk appointed June 2026. Earnings missed in May, August, and November 2026. General Counsel resigned July 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.74 → $0.89 · observed estimates
$1.59B → $1.50B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.74 | $1,594,733,333 | 1 / 2 |
| 2026-07-25 | $1.16 | $1,594,733,330 | 2 / 3 |
| 2026-07-26 | $1.16 | $1,594,733,330 | 2 / 3 |
| 2026-07-27 | $1.16 | $1,594,733,330 | 2 / 3 |
| 2026-07-28 | $1.16 | $1,594,733,330 | 2 / 3 |
| 2026-07-29 | $0.74 | $1,594,733,333 | 1 / 2 |
| 2026-07-30 | $0.74 | $1,594,733,333 | 1 / 2 |
| 2026-07-31 | $0.74 | $1,594,733,333 | 1 / 2 |
| 2026-08-01 | $0.74 | $1,594,733,333 | 1 / 2 |
| 2026-08-02 | $1.16 | $1,594,733,330 | 2 / 3 |
| 2026-08-03 | $0.74 | $1,594,733,333 | 1 / 2 |
| 2026-08-04 | $1.16 | $1,594,733,330 | 2 / 3 |
| 2026-08-05 | $1.16 | $1,594,733,330 | 2 / 3 |
| 2026-08-06 | $1.16 | $1,594,733,330 | 2 / 3 |
| 2026-08-08 | $1.04 | $1,586,433,330 | 1 / 3 |
| 2026-08-09 | $1.04 | $1,586,433,330 | 1 / 3 |
| 2026-08-10 | $1.04 | $1,586,433,330 | 1 / 3 |
| 2026-08-12 | $1.15 | $1,586,433,330 | 2 / 3 |
| 2026-08-13 | $0.73 | $1,586,433,333 | 1 / 2 |
| 2026-08-14 | $0.73 | $1,586,433,333 | 1 / 2 |
| 2026-08-15 | $0.73 | $1,586,433,333 | 1 / 2 |
| 2026-08-16 | $0.73 | $1,586,433,333 | 1 / 2 |
| 2026-08-17 | $0.73 | $1,586,433,333 | 1 / 2 |
| 2026-08-18 | $0.73 | $1,586,433,333 | 1 / 2 |
| 2026-08-19 | $0.73 | $1,586,433,333 | 1 / 2 |
| 2026-08-20 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-08-21 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-08-22 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-08-23 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-08-24 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-08-25 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-08-26 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-08-27 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-08-28 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-08-29 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-08-30 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-08-31 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-01 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-02 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-03 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-04 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-05 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-06 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-07 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-08 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-09 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-10 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-11 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-12 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-13 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-14 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-15 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-16 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-17 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-18 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-19 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-20 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-21 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-22 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-23 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-24 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-25 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-26 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-27 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-28 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-29 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-09-30 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-10-01 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-10-02 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-10-03 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-10-04 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-10-05 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-10-06 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-10-07 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-10-08 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-10-09 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-10-10 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-10-11 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-10-12 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-10-13 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-10-14 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-10-15 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-10-16 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-10-17 | $0.87 | $1,588,100,000 | 1 / 2 |
| 2026-10-18 | $0.89 | $1,502,800,000 | 1 / 2 |
| 2026-10-19 | $0.89 | $1,502,800,000 | 1 / 2 |
| 2026-10-20 | $0.89 | $1,502,800,000 | 1 / 2 |
| 2026-10-21 | $0.89 | $1,502,800,000 | 1 / 2 |
| 2026-10-22 | $0.89 | $1,502,800,000 | 1 / 2 |
| 2026-10-23 | $0.89 | $1,502,800,000 | 1 / 2 |
| 2026-10-24 | $0.89 | $1,502,800,000 | 1 / 2 |
| 2026-10-25 | $0.89 | $1,502,800,000 | 1 / 2 |
| 2026-10-26 | $0.89 | $1,502,800,000 | 1 / 2 |
| 2026-10-27 | $0.89 | $1,502,800,000 | 1 / 2 |
| 2026-10-28 | $0.89 | $1,502,800,000 | 1 / 2 |
| 2026-10-29 | $0.89 | $1,502,800,000 | 1 / 2 |
| 2026-10-30 | $0.89 | $1,502,800,000 | 1 / 2 |
| 2026-10-31 | $0.89 | $1,502,800,000 | 1 / 2 |
| 2026-11-01 | $0.89 | $1,502,800,000 | 1 / 2 |
| 2026-11-02 | $0.89 | $1,502,800,000 | 1 / 2 |
| 2026-11-03 | $0.89 | $1,502,800,000 | 1 / 2 |
| 2026-11-04 | $0.89 | $1,502,800,000 | 1 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.